Dedicated High-Performance Breast PET/CT

描述（由申请人提供）：目的：建立一个高性能，高分辨率的定量PET/CT扫描仪，专用于乳房成像。这将允许在局部分期、治疗反应预测、接受保守治疗的患者随访和乳腺癌治疗新药开发的背景下验证乳房解剖代谢成像。方法：采用一种新型的高分辨率、低死区时间闪烁探测器设计，采用apd和pspmt双端读出方案，以及一种改良版的商用PET电子设备，我们将构建一个足够紧凑的PET扫描仪，以适应我们现有的乳房CT扫描仪的机架。我们将结合这两种设备，以便在相同的临床环境中对乳房进行连续成像，从而获得准确记录的高分辨率功能和解剖图像。该设备将与活检工具兼容，并可扩展，以方便胸壁和腋窝的成像。建设将分阶段进行。在每个阶段，我们将使用一个连续的测试/再测试方法，使用预先计算的基准，以便有效和及时地解决出现的问题。我们将采用最先进的图像重建技术，使用测量系统模型来最大限度地提高空间分辨率，我们将仔细实施所有必要的定量成像数据校正。我们将在30名已知乳腺癌患者的试验中比较其与全身PET/CT和MRI的表现。健康相关性：迄今为止，在诊所测试的乳腺PET成像仪是低成本、低性能的设备，不能充分评估体内的方法，也不能提供融合了3D解剖信息的3D图像（一种在体内得到充分证明的技术）。因此，分子成像在分期和再分期、对治疗研究的反应和药物开发方面的已知力量对大部分原发性乳腺癌妇女来说是不可用的。提出的设备将解决这一问题，并允许确定足够临床表现的最低成像要求-将该技术转化为患者护理的先决条件。公共卫生相关性：迄今为止，在诊所测试的乳腺PET成像仪是低成本、低性能的设备，不能充分评估体内的方法，也不能提供融合了3D解剖信息的3D图像（一种在体内得到充分证明的技术）。因此，分子成像在分期和再分期、对治疗研究的反应和药物开发方面的已知力量对大部分原发性乳腺癌妇女来说是不可用的。提出的设备将解决这一问题，并允许确定足够临床表现的最低成像要求-将该技术转化为患者护理的先决条件。

DESCRIPTION (provided by applicant): Objectives: To build a high-performance, high-resolution quantitative PET/CT scanner dedicated to imaging the breast. This will permit validation of anato-metabolic imaging of the breast in the contexts of local staging, prediction of therapeutic response, follow-up for patients receiving conservative therapy and the development of new drugs for breast cancer treatment. Methods: Using a novel high-resolution, low-dead-time scintillation detector design using a dual-ended read-out scheme using APDs and PSPMTs, and a modified version of commercial PET electronics, we will build a PET scanner compact enough to fit inside the gantry of our existing breast CT scanner. We will combine the two devices to allow sequential imaging of the breast in the same clinical setting, resulting in accurately registered high-resolution functional and anatomic images. The device will be compatible with biopsy tools and will be expandable to facilitate imaging of the chest wall and axillae. Construction will be phased. At each stage we will use a continuous test/re-test approach using pre-calculated bench-marks to permit efficient and timely resolution of arising issues. We will employ state-of-the-art image reconstruction techniques using measured system models to maximize spatial resolution, and we will carefully implement all necessary data corrections for quantitative imaging. We will compare performance with whole-body PET/CT and MRI in a trial of 30 patients with known breast cancer. Health relatedness: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care. PUBLIC HEALTH RELEVANCE: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care.